Report: Cancer clinical trials tech startup Driver shutters two months after launch
The high cost to join the platform - which combined molecular pathology labs with a mobile app - played a role in its low sign-up numbers, CEO says.
The high cost to join the platform - which combined molecular pathology labs with a mobile app - played a role in its low sign-up numbers, CEO says.